To include your compound in the COVID-19 Resource Center, submit it here.

Avonex: Phase III data; marketed to treat relapsing-remitting MS

Subset analysis of the 383-patient North American Phase III

Read the full 95 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE